ࡱ; eb  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`adfRoot Entry  \pCalc Ba=, =@ 8X@"1Calibri1Arial1Arial1Arial1Calibri1Calibri General #,##03._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_)\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\)'""($"#,##0.00_);[RED]"($"#,##0.00\);6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_) #,##0.00                + ) , *      (  (  (  $   (8  $  $ (8  $   (  (   `a/No Title"5condensed consolidated bal"3Acondensed consolidated sta$Lcondensed consolidated sta-1$Zcondensed consolidated sta-2fconsolidated cash flowsr inventoryyvnet loss per shareynote 3 accrued expenses"}note 5 stockbased compensa$note 5 stockbased compensa-1"Յnote 6 related party trans$Չnote 8 common stock warrants&gnote 8 common stock warrants-1"=comparison of the three mo"comparison of the nine mon! cash flowsitem 6 exhibitspursuant to rule 13a14a!pursuant to rule 13a14a-1"?as adopted pursuant to sec$as adopted pursuant to sec-1TX     3  @@   qPAGEPART IFINANCIAL INFORMATIONItem 1. Financial Statements (Unaudited)XCondensed Consolidated Balance Sheets as of September30, 2023 and December31, 2022{Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September30, 2023 and 2022Condensed Consolidated Statements of Changes in Stockholders Equity for the three and nine months ended September30, 2023 and 2022iCondensed Consolidated Statements of Cash Flows for the nine months ended September30, 2023 and 2022BNotes to Unaudited Condensed Consolidated Financial StatementsItem 2.YManagement s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.>Quantitative and Qualitative Disclosures about Market RiskItem 4.Controls and ProceduresPART IIOTHER INFORMATIONLegal ProceedingsItem 1A. Risk Factors?Unregistered Sales of Equity Securities and Use of ProceedsDefault Upon Senior SecuritiesMine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits Signatures%Condensed Consolidated Balance Sheets September30, December31,20232022Assets (Unaudited)Current assetsCash and cash equivalentsMarketable securities-Accounts receivable, net of allowance for doubtful accounts of $ 24,507 and $ 6,016 as of September30, 2023 and December31, 2022, respectivelyOther receivables InventoryPrepaid expensesTotal current assets Other assetsProperty and equipment, net"Operating lease right-of-use asset Total assets$Liabilities and Stockholders EquityCurrent liabilitiesAccounts payableAccrued expenses*Current portion of finance lease liability,Current portion of operating lease liabilityTotal current liabilitiesNon-current liabilities-Finance lease liability, less current portion/Operating lease liability, less current portion,Non-convertible promissory notes - long-termTotal non-current liabilitiesTotal liabilities&Commitments and contingencies (Note 9)Stockholders equityhPreferred stock, $ 0.00001 par value; 20,000,000 shares authorized; 0 shares issued and outstandingCommon stock, $ 0.00001 par value; 300,000,000 shares authorized; 380,648 and 330,648 shares issued and outstanding as of September30, 2023 and December31, 2022, respectivelyAdditional paid-in capitalAccumulated deficit&Accumulated other comprehensive incomeTotal stockholders equity*Total liabilities and stockholders equity7Condensed Consolidated Statements of Comprehensive Loss#Three months ended September30,"Nine months ended September30,RevenueSales$- Grant revenue Total revenue Cost of sales Gross profitOperating expensesResearch and developmentGeneral and administrativeTotal operating expensesOperating lossOther (income) and expensesInvestment income/Unrealized loss (gain) on marketable securities&Realized loss on marketable securitiesInterest expenseNet lossOther comprehensive income>Reclassification adjustment for net gains included in net loss Net changeTotal comprehensive loss&Net loss per share - basic and diluted2Weighted average common shares - basic and dilutedCCondensed Consolidated Statements of Changes in Stockholders EquityPreferred StockCommon StockAdditional Paid-In#Accumulated Other Comprehensive AccumulatedTotal Stockholders SharesAmountCapitalIncome (Loss)DeficitEquity#Balance as of December31, 2022$Stock-based compensation expense<Issuance of common stock, net of issuance costs of $ 300,750Other comprehensive income Net loss Balance as of March 31, 2023Balance as of June 30, 2023$Balance as of September30, 2023Preferred Stock Common StockAccumulated Other ComprehensiveTotal Stockholders Income (Loss)Balance as of December31, 2021 Stock-based compensation expenseBalance as of March 31, 2022Balance as of June 30, 2022 Balance as of September30, 2022Consolidated Cash Flows$Cash Flows from Operating ActivitiesJAdjustment to reconcile net loss to net cash used in operating activities: DepreciationWrite-off of obsolete inventory/Unrealized gain on marketable equity securities=Realized (gain)/loss on marketable debt and equity securitiesProvision for bad debtsStock-based compensationNon-cash lease expense+Changes in operating assets and liabilitiesAccounts receivable, net%Net cash used in operating activities$Cash Flows from Investing ActivitiesPurchases of lab equipment'Purchases of marketable debt securities3Proceeds from sales of marketable equity securities&Maturity of marketable debt securities)Net cash provided by investing activities$Cash Flows from Financing Activities-Proceeds from issuance of common stock, gross*Payment for issuance costs of common stock%Repayments of finance lease liability)Net cash provided by financing activities)Net increase in cash and cash equivalents.Cash and cash equivalents, beginning of period(Cash and cash equivalents, end of periodTSupplemental disclosure of cash flow information and non-cash financing transactions3Right-of-use asset acquired through operating lease+Fixed assets acquired through finance leaseDLeasehold improvements financed through tenant improvement allowance Raw materialsWork in processTotal inventoryNet Loss per Share September 30,Restricted stock units Stock optionsWarrants for common stockNote 3 Accrued ExpensesAccrued interestAccrued bonusesOther Note 5 Stock-based CompensationNumber of Options6Weighted- Average Exercise Price per ShareEWeighted Average Remaining Contractual Term (in Years)#Outstanding as of December31, 2022Granted$Outstanding as of September 30, 2023!Exercisable at September 30, 2023Number of Shares8Weighted- Average Exercise Priceper ShareFWeighted Average Remaining Contractual Term (inYears)!Outstanding of September 30, 2023"Note 6 Related Party TransactionsGenomic Diagnostic TechnologiesSt. Laurent InstituteSt. Laurent Realty, Inc.Note 8 Common Stock Warrants Number ofIssuableUpon Exercise of OutstandingExercise Issuance DateWarrantsPriceExpirationDate 10/17/2018 10/16/2023 11/2/2018 11/1/2023 11/9/2018 11/8/2023 11/16/2018 11/15/2023 11/29/2018 11/28/2023 12/21/2018 12/20/2023 12/27/2018 12/26/2023 1/31/2019 1/30/20242/7/20192/6/2024 2/21/2019 2/20/2024 3/20/2019 3/18/20244/8/20194/6/2024 11/19/2020 6/30/20241/8/2021 1/11/2021 2/13/2021 3/16/2021 8/31/2021 8/31/2026 8/26/2026 9/29/2021Operating LeaseFinance Lease2023 (remaining) Thereafter$Total undiscounted lease liabilitiesLess effects of discountingTotal lease liabilities@Comparison of the Three Months Ended September 30, 2023 and 2022#Three months ended September 30,?Comparison of the Nine Months Ended September 30, 2023 and 2022"Nine months ended September 30, Cash FlowsNine Months Ended$Cash proceeds (used in) provided by:Operating activitiesInvesting activitiesFinancing activitiesItem 6. ExhibitsExhibit Number DescriptionCertification of the Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Certification of the Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley<: Act of 2002.Certifications of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Certifications of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101.INSInline XBRL Instance Document.101.SCH/Inline XBRL Taxonomy Extension Schema Document.101.CAL=Inline XBRL Taxonomy Extension Calculation Linkbase Document.101.DEF<Inline XBRL Taxonomy Extension Definition Linkbase Document.101.LAB7Inline XBRL Taxonomy Extension Label Linkbase Document.101.PRE>Inline XBRL Taxonomy Extension Presentation Linkbase Document.YCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).PURSUANT TO RULE 13A-14(A)By:/s/ Daniel JonesName: Daniel JonesTitle:Chief Executive Officer/s/ Frances ScallyFrances ScallyChief Financial OfficerDAS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Date:November 20, 2023 S/*cc   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } d} }  } ,,,@@@@@ @ @ , , ,,@,,,,,   ~   ~  ~  ~  ~  ~   ~    ~ B   ~ ^  ~ ^  ~ b  ~ b  ~ b  ~ f  ~ f  ~ f  ~ f  ~ f ~ jPH0(  >@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} d} }  } }  } ),,,,,,, , , , , ,,,,,,,,,,,,,,,,,,,      ! " #  $   %~ |~  & '~ V (~ *~ zK ) '~  * '~ r + '~ N} ,~ V~ " - .~ (~ Z /~ r>~ D -~ ~ B 0~ V*P~  1 2 3~ b~ % 4~ ~ = 5~ v ' 6~  ~  7~ =~ J 8 9~  ' :~  =~ /~  ,!,",#,$,%,&,',(, > !? "@ "' "' #A~ #~ # $B~ $^^~ $r %C~ %B~ %Q &D &'~ &^ 'E~ 'j~ '  (F~ (V*P(~ ((((((PH 0(  >@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} >} }  } }  }  } } }  } ,@,,,,, , , , , ,,,,,,,,,,,,,,, G H  I    !     ! J      K L L  L ~ f M ' '  '~  N ' '  '~  O ' ' '~  P ' ' '~ F Q R~ ~ +~ l~ D S~ 5~ ~ ~ g T~ «N~ 8~  ~ 괬 U~ BT~ r~  f~ ^ X V W~ V~ d~  Z~  X '~   '~  Y ' '  '~ R} Z~ ]~  ~  ~ b} [~ ~ |~  rJ~ Q \ ] ' '~  6 ' ^ ' '~  6 ' _~ ~ |~   ~ Q `~ ~ ~   ~  a~ ;~ b.~  ں~ b.      PH0 0(   >@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} <} } } } }  } } }  } }  } }  } }  } }  }  , @ @ @ @ , @ @ @ @ @ @ @ @ @ @ b c  d  e f g h i j  i  j k l m n o ' L~  b.~ ~ r~ ^~ Q~   p ' '  ' '~   ' '~   q ' '~  B ~ ~ Ɓ[ ' '~ ʁ[ r ' '  ' ' '~ ~  s ' ' ' ' ' '~ ~  t ' L ~ ;~  ~ >d ~ N ~ Zp- ~   p ' ' ' '~  ' '~  r ' ' ' ' '~  '~  s ' ' ' ' ' '~ :~ : u ' L~  ;~ ~ B L~ ~ ޱ p ' '  ' '~ { ' '~ { s ' '  ' ' ' '~ ~  v ' L~  ;~ ~ ^^ L~ B~ j2&        PH@0(  >@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } } } } }  } } } } }  } } } }  } }  }   , , , , , , , , , , , , w  x   y g z i j  i  j k { m n | ' L~  b.~ ~ )c L~ ?~ i } ' '  ' '~ i ' '~ i [ ' '  ' ' ' '~ z~ z ~ ' L~  b.~ ~ f L~ W~  } ' '  ' '~  ' '~  [ ' '  ' ' ' '~ vF~ vF  ' L ~ b.~  ~ Vj  L ~ F ~   } ' ' ' '~  ' '~  [ ' ' ' ' ' '~ |~ |  ' L ~ b.~  ~ &n  L ~  ~ P *%              PHP0(  >@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} T} }  } }  } *,@,,,,, , , , , ,,,,,,,,,,,,,,,,,,,  I   !    [~ rJ~ Q  ~ &~ z ~ r '  '~  ~ ~ R} ~ n ' ~ ~ F ~ #~    '~  ) '~ x +~ F3~ f * '~  -~ k~ H 3~ ~ Fo 4~ 6~  ~ n ~ v+N  ~ n7~ 0 ~ U~ nag  '~ jg ~ ] ' ~ f~ r  ~ m ' ,!,",#,$,%,&,',(,), ~ ʤ ' !~ !~s !' "~ "FY "' #~ #f^~ # $~ $~ $b %~ %|%~ %F% & ' 'L'~ '^L' (~ (q ( (L( ) )L)~ ))%%%%''''(((())))PH`0(  >@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } } } }  } ,,,,,, *     !  L~   '~ v'  L~ r J PHp0(  >@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } }  } }  } ,,,,,,     ! ~  ' ~ ~  ~ :~ &"PH 0(   >@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } } } }  }  ,,,,,,,      ! ~ ~   '~ b=  '~ &F~ ~ =J PH$0(  $>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} $} }  }  } }  , @ , , , ,       ~ ~  u ~  ! ~ ~  S ~  !* ~ ~  +c ~  ! ~   (\S@ ~  !gB PH(0(  (>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} #} }  }  } }   @ , , , ,       ' L  ' ~ ~  ( ~  !* ~ ~  ( ~  !  ' L  ': PH,0(  ,>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } }  } }  }  ,,,,,,,      !  L~ v  '~ / ~ v~ v~ v~ J PH00(  0>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } }  }  } } ! ,,,,,,, , , , , , , , , , , , , , , , , , , , , , , ,    i                ~ v~     ~ b~     ~ b~     ~ b~     ~ b~     ~ b~     ~ b~     ~ ~     ~ ~     ~ ~     ~ R~     ~ ~     ~ ~     ~ V~     ~ 6~     ~ n ~     ~ 6~     ~ .~     ~ 6~     ~ ^~     ~ ;~     ~ ~     ,~ :*%      PH40(  4>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} $} }  } }  }  @,,,,,,, , ,   ~ -~ ~ ~ ~ j~ ~ W~ &P~ ~  '~ ~ Bf ' ~ {! ' ~ l~  ~ ~ : ~  [ ~  B  PH80(  8>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} >} }  } }  } ,@,,,,, , , , , ,,,,,,,,,,,,,,,     ! J   K L L M ' ' N ' ' O ' ' P ' ' Q R~ ~ + S~ 5~  T~ «N~ 8 U~ BT~ r V W~ V~ d X '~  Y ' ' Z~ ]~   [~ ~ | \ ] ' ' ^ ' ' _~ ~ | `~ ~  a~ ;~ b.b PH<0(  <>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} >} }  } }  } ,@,,,,, , , , , ,,,,,,,,,,,,,,,     ! J   K L~ f M '~  N '~  O '~  P '~ F Q R~ l~ D S~ ~ g T~ ~ 괬 U~ f~ ^ X V W~ Z~  X '~  Y '~ R} Z~ ~ b} [~ rJ~ Q \ ]~ 6 ' ^~ 6 ' _~ ~ Q `~ ~  a~ ں~ b.b PH@0(  @>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} )} }  } }  }  ,,,,,,, , ,      !    ~ n ~ v+N ~ f~ r ~ FY ' ~ f^ ~  Z   PHD0(  D>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } } d} ,@,,,,, , , , , ,,  " ~ !0 ~ !0 ~ !+2 !@@                 ~    PH H0(  H>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } } } ,,,,   ##    PH0L0(  L>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } } } ,,,,   ##    PH@P0(  P>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } } ,,,,,   $       PHPT0(  T>@<dgg   d-C6?_%,*+&gfffff?'gfffff?(?)?" d,, `? `?U} } } ,,,,,   $       PH`X0(  X>@<dgg  FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@J\@J\՜.+,D՜.+,\P 8@ AppVersion12.0000Root EntryFc@WorkbookCompObjIOle SummaryInformation(DocumentSummaryInformation8